POTELIGEO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTELIGEO (POTELIGEO).
Mogamulizumab is a defucosylated humanized anti-CCR4 monoclonal antibody that binds to CCR4 on the surface of cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and depleting CCR4-expressing cells, including malignant T cells and regulatory T cells (Tregs).
| Metabolism | Mogamulizumab is a monoclonal antibody; metabolism is via catabolic pathways into small peptides and amino acids. No specific metabolic enzymes identified. |
| Excretion | POTELIGEO (mogamulizumab) is a monoclonal antibody, primarily eliminated via intracellular catabolism into amino acids. No quantitative data on renal or biliary excretion; minimal to no excretion as intact antibody in urine or feces. |
| Half-life | Terminal elimination half-life is approximately 17 days (range 11–22 days) at steady state, supporting every-2-week or every-4-week dosing intervals. |
| Protein binding | Approximately 95% bound to plasma proteins, predominantly to immunoglobulins and albumin as a therapeutic monoclonal antibody. |
| Volume of Distribution | Volume of distribution at steady state (Vss) is approximately 5.1 L (range 3.8–6.7 L), indicative of limited extravascular distribution, consistent with a monoclonal antibody primarily confined to vascular and interstitial spaces. |
| Bioavailability | Only intravenous administration; intravenous bioavailability is 100% by definition. |
| Onset of Action | Clinical response (e.g., reduction in circulating Sézary cells) observed as early as 4 weeks after first intravenous infusion; maximal response may require several cycles. |
| Duration of Action | Duration of therapeutic effect continues throughout treatment course; after discontinuation, pharmacodynamic effects (e.g., depletion of CCR4-positive cells) persist for weeks to months, correlating with antibody clearance. |
3 mg/kg intravenously over 60 minutes on days 1, 8, and 15 of each 28-day cycle.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl 30-89 mL/min). Insufficient data for severe renal impairment (CrCl <30 mL/min) or dialysis. |
| Liver impairment | No dose adjustment required for Child-Pugh A or B. Insufficient data for Child-Pugh C. Use with caution. |
| Pediatric use | Safety and effectiveness not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended. Monitor for adverse effects more frequently due to potential age-related renal and hepatic function decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTELIGEO (POTELIGEO).
| Breastfeeding | It is unknown whether mogamulizumab is excreted in human milk. Human IgG is present in breast milk, but concentrations are generally low. The M/P ratio has not been determined. Due to the potential for serious adverse reactions in the breastfed infant (e.g., immunosuppression), women should not breastfeed during treatment and for at least 5 half-lives (approximately 5 weeks) after the last dose. |
| Teratogenic Risk | POTELIGEO (mogamulizumab) is a monoclonal antibody. IgG antibodies cross the placenta increasingly after the first trimester, with peak transfer in the third trimester. Based on its mechanism of action (CCR4-directed cytolytic activity), there is potential for fetal harm, including depletion of maternal and fetal T-cell subsets, especially regulatory T cells, which are critical for immune tolerance. Animal studies have not been conducted, but given the pharmacodynamics, use during pregnancy should be avoided unless clearly necessary. First trimester exposure carries theoretical risks of altered immune development; second and third trimester exposure may cause fetal lymphopenia and increased infection risk. |
■ FDA Black Box Warning
WARNING: DERMATOLOGIC TOXICITY. Severe, including fatal, dermatologic adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred. Discontinue for suspected severe cutaneous adverse reactions.
| Serious Effects |
["None"]
| Precautions | ["Infusion reactions: Monitor during infusion; interrupt or discontinue based on severity.","Dermatologic toxicity: Severe skin reactions including SJS/TEN; discontinue if suspected.","Immune-mediated adverse reactions: including pneumonitis, hepatitis, colitis, endocrinopathies, and others.","Infections: Fatal infections occurred; monitor for infections and treat promptly.","Autoimmune hemolytic anemia: Fatal cases reported.","Posterior reversible encephalopathy syndrome (PRES): Discontinue if suspected.","Hematologic toxicity: Monitor blood counts; severe neutropenia, thrombocytopenia, and anemia reported.","Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception."] |
Loading safety data…
| Fetal Monitoring | Monitor complete blood counts (CBC) with differential, including lymphocyte counts, before and during therapy. Assess liver function tests (LFTs) and renal function. Monitor for infections, infusion-related reactions, and skin toxicity (e.g., Stevens-Johnson syndrome). Obtain pregnancy test in women of reproductive potential prior to initiation. Fetal monitoring: Consider serial ultrasound for growth assessments if used in pregnancy, though no specific fetal monitoring guidelines exist. |
| Fertility Effects | No human data on fertility effects. In animal studies with an anti-CCR4 antibody, no adverse effects on male or female fertility were observed. However, based on the mechanism, potential for disruption of immune homeostasis and possible effects on reproductive tissues expressing CCR4 cannot be excluded. Women of childbearing potential should use effective contraception during treatment and for at least 3 months after the last dose. |